1. KD Tripathi MD. Anti-emetic, prokinetic and digestant drugs. Essentials of Medical Pharmacology 7thed. New Delhi, May 2013. Page – 669.
2. Qingqing Qi, Yan Zhang, Feixue Chen, Xiuli Zuo & Yanqing Li. Ramosetron for the treatment of irritable bowel syndrome with diarrhea: a systematic review and meta-analysis of randomized controlled trials: BMC Gastroenterology, Jan 08, 2018; [Accessed Jan 02, 2021] https://bmcgastroenterol.biomedcentral.com/articles/10.1186/s12876-017-0734-2
3. Toshimi Chiba, Kazunari Yamamoto, Shoko Sato, and Kazuyuki Suzuki. Long-term efficacy and safety of ramosetron in the treatment of diarrhea-predominant irritable bowel syndrome, July 25, 2013; [Accessed Jan 02, 2021] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3728153/#:~:text=3%2C4%20Ramosetron%2C%20a%20potent,patients%20suffering%20from%20IBS%2DD.
4. Jayesh J. Sanmukhani, Prafulla Pawar, and Ravindra Mittal. Ramosetron hydrochloride for the prevention of cancer chemotherapy induced nausea and vomiting: The Indian experience: South Asian journal of cancer. 2014 Apr-Jun; [Accessed Jan 02, 2021] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4014645/